From the magazine

Why the Canadian Immunization Guide should be our first stop for vaccination decision-making
Vaccinations are an important—but not the only—component of any travel consultation.
Where to start?
We do not want to stop medications that are safely helping to treat symptoms, but we could think about ‘legacy prescriptions’ which people may have been taking for many years without re-evaluation.

Safety of combining PDE5 inhibitors and nitrates

Some studies have demonstrated lower mortality with phosphodiesterase-5 inhibitor treatment for erectile dysfunction in men with stable coronary artery disease, compared with no treatment.
Understanding the interplay of menopausal hormone therapy and dementia

For women under the age of 65 years, especially those under the age of 55 years, there appears to be no increased risk of dementia with MHT.
Breaking the cycle: A pharmacist’s guide to prevention and management of recurrent UTIs in women

Up to 50% to 60% of women will have a urinary tract infection in their lifetime, and up to 25% to 30% of these women will have a recurrent UTI.
Five tips for keeping pediatric patients safe in community practice

Evidence suggests that errors in pediatric prescriptions are three times more likely to cause harm compared to those related to adults.
GLP-1 agonists and suicidality

Cases of suicidality have been reported among patients using GLP-1 receptor agonists for diabetes and/or obesity.
Embracing innovation in community pharmacy: A three-pronged approach

Innovation doesn’t always require new services or clinical niches; it can also mean reimagining how existing services are delivered.
Drug news—May 2024

A review of new launches, new indications, new dosage forms and Health Canada advisories.
Editorial: Two simple questions

I’m amazed that even after two decades of focusing on innovative practitioners, I continue to meet people who are launching inspiring new pharmacy career options.

Why the Canadian Immunization Guide should be our first stop for vaccination decision-making

Where to start?

Safety of combining PDE5 inhibitors and nitrates

Understanding the interplay of menopausal hormone therapy and dementia

Breaking the cycle: A pharmacist’s guide to prevention and management of recurrent UTIs in women

Five tips for keeping pediatric patients safe in community practice

GLP-1 agonists and suicidality

Embracing innovation in community pharmacy: A three-pronged approach

Drug news—May 2024

Editorial: Two simple questions